Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
CILOXAN is a topical ophthalmic ointment containing ciprofloxacin hydrochloride, a fluoroquinolone antibiotic approved in 1998. It treats bacterial conjunctivitis by interfering with bacterial DNA gyrase, achieving clinical cure in approximately 75% of patients with positive conjunctival cultures. The formulation achieves minimal systemic absorption (<2.5 ng/mL), making it well-suited for localized ocular therapy.
Product is in LOE-approaching phase with moderate competitive pressure (30%), signaling a mature team focused on brand defense and lifecycle extension rather than growth expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CILOXAN offers exposure to mature product management, healthcare provider education, and defensive competitive positioning in ophthalmology. This is an ideal role for professionals seeking stability in a legacy franchise while navigating LOE strategy and lifecycle extension initiatives.
Worked on CILOXAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo